The antibody-binding site, through which an antibody binds to its epitope, is a complex structure formed by the folding together of six complementarity-determining regions (CDRs). However, certain peptides derived from CDR sequences retain antibody specificity and function; these are know as microantibodies (MicroAbs). For example, the F58 MicroAb is a 17 residue, cyclized peptide (CDLIYYDYEEDYYFDYC) derived from CDR-H3 of F58, an IgG1 specific for the gp120 envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1). Both MicroAb and IgG recognize the same epitope in the V3 loop and, despite its small size, the MicroAb neutralizes the infectivity of HIV-1 IIIB only 32-fold less efficiently on amolar basis. The advantage of MicroAb...
We sought to identify sequences in the monoclonal antibody m18 complementarity determining regions (...
447-52D is a human monoclonal antibody isolated from a heterohybridoma derived from an HIV-1-infecte...
The identification and characterization of broadly neutralizing antibodies (bnAbs) against HIV-1 has...
The antibody-binding site, through which an antibody binds to its epitope, is a complex structure fo...
Only two virus-neutralizing peptide microantibodies (MicroAbs) have been described and little is kno...
Progress in therapeutic or prophylactic immune intervention in HIV-1 infections may only come about ...
AbstractBackground: The protein 0.5β is a potent strain-specific human immunodeficiency virus type 1...
Antibody molecules, produced as a response against foreign substances, interact with their antigen i...
A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein gp120 of...
We have analyzed a panel of eight murine monoclonal antibodies (MAbs) that depend on the V2 domain f...
Antibody molecules, produced as a response against foreign substances, interact with their antigen i...
Thirty-six monoclonal antibodies from mice and three from rats were raised against a peptide corresp...
We investigated the interaction between cross-reactive HIV-1 neutralizing human monoclonal antibody ...
The 4E10 antibody recognizes the membrane-proximal external region (MPER) of the HIV-1 Env glycoprot...
One potential approach to vaccine development against HIV involves generating an immunogen that can ...
We sought to identify sequences in the monoclonal antibody m18 complementarity determining regions (...
447-52D is a human monoclonal antibody isolated from a heterohybridoma derived from an HIV-1-infecte...
The identification and characterization of broadly neutralizing antibodies (bnAbs) against HIV-1 has...
The antibody-binding site, through which an antibody binds to its epitope, is a complex structure fo...
Only two virus-neutralizing peptide microantibodies (MicroAbs) have been described and little is kno...
Progress in therapeutic or prophylactic immune intervention in HIV-1 infections may only come about ...
AbstractBackground: The protein 0.5β is a potent strain-specific human immunodeficiency virus type 1...
Antibody molecules, produced as a response against foreign substances, interact with their antigen i...
A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein gp120 of...
We have analyzed a panel of eight murine monoclonal antibodies (MAbs) that depend on the V2 domain f...
Antibody molecules, produced as a response against foreign substances, interact with their antigen i...
Thirty-six monoclonal antibodies from mice and three from rats were raised against a peptide corresp...
We investigated the interaction between cross-reactive HIV-1 neutralizing human monoclonal antibody ...
The 4E10 antibody recognizes the membrane-proximal external region (MPER) of the HIV-1 Env glycoprot...
One potential approach to vaccine development against HIV involves generating an immunogen that can ...
We sought to identify sequences in the monoclonal antibody m18 complementarity determining regions (...
447-52D is a human monoclonal antibody isolated from a heterohybridoma derived from an HIV-1-infecte...
The identification and characterization of broadly neutralizing antibodies (bnAbs) against HIV-1 has...